Programs

HomePrograms ▶ Partner Grants without LOI Stage
Partner Grants without LOI Stage

Important Notes

Applicants are strongly advised to read the instructions and eligibility criteria before starting an application.
Letters of Intent (LOI) are available on the Foundant Technologies Website.
Grants below skip the letter of intent (LOI) stage and do not require an invitation to submit a full application.


Anticipated Timeline

July 20, 2021 Application Period Opens
January 11, 2022 Full Application Deadline due by 11:59 pm Eastern Time
March 2022 Grantee Notification
April/May 2022 Grant Start Date

 

Partner Grant Opportunities (with no LOI)

4DMedical

ATS/4DMedical Research Grant in Asthma using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS)

1 grant available
$50,000 for 1 year

Target Audience:
Early-stage investigators interested in research in Asthma using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS) 

The focus of this research grant is proposals that are conducting research in asthma using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS). Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution. 

Award-specific eligibility:
• Early-stage investigators (as defined here)  
• Must meet eligibility requirements for all grants found here

Fully funded by 4DMedical. Please visit 4dmedical.com for more information about our partner. 

 

4DMedical

ATS/4DMedical Research Grant in IPF using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS)

1 grant available
$50,000 for 1 year

Target Audience:
Early-stage investigators interested in research in IPF using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS)

The focus of this research grant is proposals that are conducting research in IPF using X-ray Velocimetry (XV) Lung Ventilation Analysis Software (LVAS). Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution.

Award-specific eligibility:
• Early-stage investigators (as defined here)   
• Must meet eligibility requirements for all grants found here

Fully funded by 4DMedical. Please visit 4dmedical.com for more information about our partner.

Alpha-1 Foundation

ATS/Alpha-1 Foundation Research Grant
1 grant available
$40,000 per year for 2 years

Target Audience:
Investigators (early-stage or established) interested in research that is relevant to alpha-1 antitrypsin deficiency (Alpha-1)

The focus of this research grant is proposals that have a high likelihood to advance the understanding of Alpha-1. Applications are encouraged from faculty members at any stage of their academic career. Applicants may request up to $40,000 per year for two years for salaries, supplies, or a combination of these two. Indirect costs will not be paid to the sponsoring institution.

Award-specific eligibility:
• Early-stage investigators (as defined here) OR established investigators at any stage in their career
• Applicants must not be current awardees of the Alpha-1 Foundation Research Program 
• Must meet eligibility requirements for all grants found here

Co-funded by the ATS and the Alpha-1 Foundation.

fisher & paykel

ATS/Fisher & Paykel Healthcare Research Grant in Nasal High Flow

1 grant available
$50,000 for 1 year

Target Audience:
Early-stage investigators interested in research on respiratory support with nasal high flow therapy for hospital patients

The focus of this research grant is proposals on respiratory support with nasal high flow therapy for hospital patients. Nasal high flow (NHF) therapy refers to a typical range from 20 to 70 L/min of heated, humidified gas delivered to the nares via purposely designed nasal cannula. Flow settings and fraction of delivered supplemental oxygen during the therapy vary depending on the patient’s level of compliance and severity of disease. There has been a recent rapid uptake in the use of NHF in acute care settings, primarily to treat hypoxemic respiratory failure, and the therapy has been extensively used around the world during the COVID-19 pandemic. Apart from efficient oxygenation due to the prevention of room air entrainment, NHF provides respiratory support that may be seen in the reduction of the breathing frequency and the work of breathing. Positive airway pressure and the reduction of re-breathing caused by the clearance of expired gas in the upper airways are believed to be the key mechanisms that may improve the ventilation efficiency during NHF. Saturation with water of heated gas maintains hydration of the airway surface liquid and preserves mucociliary function.

NHF therapy is increasingly used in stable patients with lung disease or post-surgery who require support during unassisted breathing with little or no supplemental oxygen. Fisher & Paykel Healthcare, in collaboration with the American Thoracic Society, seeks to offer a research award to investigators interested in studying these potential benefits of NHF. The prospective study could be aimed at better understanding the mechanisms of action of this therapy, or on achieving improvements in a variety of likely outcomes. 

Applicants may request up to $50,000 for 1 year. Granted funds may be used to provide salary support for the PI or ancillary staff, to purchase supplies and/or reagents, or subject enrollment fees directly related to the project or other allowable costs. Travel for the PI for purposes of presenting data related to the project is limited to $2,000 per year. Indirect costs will not be paid to the sponsoring institution.

Award-specific eligibility: 
• Early-stage investigators (as defined here) 
• Must meet eligibility requirements for all grants found here

Fully funded by Fisher & Paykel Healthcare.


Review Process

Please note that after you submit your application it will be reviewed by Research Program staff. If there are any problems or if these guidelines have not been followed, your proposal will be un-submitted. Please make sure that you check your email after you submit your application so that any outstanding issues may be addressed as quickly as possible.

The ATS Scientific Grant Review Committee (SGRC)* will review the applications at the end of February/beginning of March 2022. The membership of the SGRC is listed on the ATS Website and additional ad hoc reviewers will be invited to participate as needed. Funding decisions will be made on the basis of scientific merit, novelty, and responsiveness to the purpose of the specific grant program.

*previously known as the Scientific Advisory Committee (SAC)


ATS Policy on Additional Grant Funding

Simultaneous submission of grants with scientific overlap is allowed, but if multiple applications are funded, then the applicant must notify the Research Program within one month of formal notification of award. A subcommittee of the SGRC will assess the degree of overlap. In the case of significant scientific overlap, the applicant will have to choose between the ATS Foundation research grant and the other grant. Budgetary overlap is not allowed.


If your question is not answered in the FAQ, contact the Research Program at researchprogram@thoracic.org.

 

The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

Twitter Facebook LinkedIn Instagram YouTube Social Media Page

AMERICAN THORACIC SOCIETY
25 Broadway
New York, NY 10004
United States of America

Phone: +1 (212) 315-8600
Fax: +1 (212) 315-6498
Email: atsinfo@thoracic.org

© 1998 - American Thoracic Society, all rights reserved.